‌

US Patent 12064420 Tie-2 activators targeting the Schlemm's canal

Patent 12064420 was granted and assigned to EyePoint Pharmaceuticals on August, 2024 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors

Is a

0

Patent attributes

Patent Applicant

EyePoint Pharmaceuticals

0

Current Assignee

EyePoint Pharmaceuticals

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Kevin Peters0

Date of Patent

August 20, 2024

0

Patent Application Number

175698380

Date Filed

January 6, 2022

0

Patent Citations

US Patent 7589212 Human protein tyrosine phosphatase inhibitors and methods of use

0

US Patent 7622593 Human protein tyrosine phosphatase inhibitors and methods of use

0

US Patent 7632862 Pharmaceutical compositions that modulate HPTPbeta activity

0

US Patent 7740846 Inhibitors of angiopoietin-like 4 protein, combinations, and their use

0

US Patent 7769575 Three dimensional coordinates of HPTPbeta

0

US Patent 7795444 Human protein tyrosine phosphatase inhibitors and methods of use

0

US Patent 7973142 Antibodies that bind human protein tyrosine phosphatase beta (HPTPβ)

0

US Patent 8106078 Human protein tyrosine phosphatase inhibitors and methods of use

0

...

Patent Primary Examiner

0

CPC Code

0

0

0

Patent abstract

Disclosed herein are compounds effective for activation of Tie-2 and inhibition of HPTP-beta. The compounds can provide effective therapy for eye conditions, for example, intraocular pressure, ocular hypertension, and glaucoma.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 12064420 Tie-2 activators targeting the Schlemm's canal

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool

By using this site, you agree to our Terms of Service.